Can I Take Resveratrol with Rapamycin (Sirolimus)?

What Happens Pharmacokinetically When You Combine These Two?

Resveratrol is a moderate inhibitor of CYP3A4 and P-glycoprotein (P-gp). Sirolimus depends almost entirely on CYP3A4 for hepatic and intestinal metabolism, and on P-gp for intestinal efflux. When resveratrol reduces both of these clearance routes simultaneously, sirolimus bioavailability increases and its elimination half-life extends. The practical result is higher sirolimus blood concentrations from the same oral dose.

CYP3A4 Inhibition: What the Data Show

In vitro studies confirm that trans-resveratrol inhibits CYP3A4 activity. A 2009 investigation published in Drug Metabolism and Disposition demonstrated concentration-dependent CYP3A4 inhibition by resveratrol with a Ki in the low-micromolar range, which is achievable with standard supplement doses of 250 to 500 mg daily (1). Sirolimus itself has one of the narrowest therapeutic indices of any commonly prescribed drug, and a relatively small shift in CYP3A4 activity translates directly into trough-level excursions.

The FDA prescribing information for Rapamune (sirolimus) explicitly lists CYP3A4 inhibitors as drugs that raise sirolimus exposure and require dose adjustment or avoidance (2). Resveratrol is not called out by name, because supplement interactions are rarely included in drug labeling, but its mechanism fits the same pharmacokinetic profile as ketoconazole or erythromycin, which are both cited as strong to moderate CYP3A4 inhibitors in that label.

P-Glycoprotein Inhibition

P-gp acts as a cellular pump that limits intestinal absorption of sirolimus. Resveratrol has been shown to inhibit P-gp in Caco-2 intestinal cell models, reducing efflux and increasing drug permeation (3). This compounds the CYP3A4 effect: both mechanisms point toward increased sirolimus absorption and reduced clearance. The combination does not merely add to sirolimus exposure, it multiplies it through two independent pathways acting on the same drug.

Practical Magnitude: How Much Could Levels Rise?

No dedicated human pharmacokinetic study has measured resveratrol's effect on sirolimus trough concentrations in vivo. This is a genuine gap in the literature. A comparable moderate CYP3A4 inhibitor, verapamil, raises sirolimus AUC by roughly 2-fold when co-administered (4). Resveratrol's inhibitory potency is lower than verapamil's, so a 30 to 70% increase in sirolimus exposure is a clinically plausible estimate, not a confirmed figure. Even a 30% rise matters when trough targets are already narrow.

Pharmacodynamic Overlap: Both Compounds Target mTOR

The pharmacokinetic concern is the more urgent clinical issue, but the pharmacodynamic picture deserves equal attention. Sirolimus is an allosteric inhibitor of mTORC1. Resveratrol activates SIRT1 (sirtuin-1) and AMPK, both of which suppress mTOR signaling by independent upstream mechanisms (5). The two compounds converge on mTOR through different molecular addresses, which means their effects may be additive or even synergistic in suppressing mTORC1 output.

Is Additive mTOR Suppression Beneficial or Harmful?

Proponents of the combination argue that deeper mTOR suppression could amplify longevity benefits. The ITP (Interventions Testing Program) at the National Institute on Aging showed that rapamycin extended median lifespan in mice by 9 to 14% when started at 20 months of age (6). Resveratrol also showed lifespan benefits in some mouse models, though the ITP's own replication attempts produced inconsistent results (7). Neither study involved the combination.

Excessive mTOR suppression in humans, however, carries real costs. MTORC1 inhibition impairs wound healing, suppresses immune surveillance (relevant even at low longevity doses), and disrupts insulin signaling through S6K1 feedback on IRS-1, a paradox that has been documented with sirolimus monotherapy in multiple metabolic studies (8). Adding resveratrol's SIRT1/AMPK-mediated mTOR suppression on top of sirolimus could deepen these effects without providing additional benefit that has been demonstrated in humans.

mTOR and Immune Function at Longevity Doses

The off-label longevity community typically uses sirolimus at doses of 1 to 6 mg once weekly, which is far below the 2 to 5 mg daily dosing used in transplant recipients. At these lower doses, trough levels often sit at 1 to 5 ng/mL rather than the 4 to 20 ng/mL range required post-transplant. Still, the enzyme inhibition from resveratrol operates regardless of the dose of sirolimus being used, any increase in sirolimus exposure is proportional, not threshold-dependent.

Estrogenic Activity of Resveratrol: A Separate Concern

Resveratrol is a phytoestrogen. It binds estrogen receptors ERα and ERβ with greater affinity for ERβ, acting as a selective estrogen receptor modulator (SERM) at physiologic concentrations (9). This is generally considered a secondary issue in the context of sirolimus co-administration, but it becomes relevant for specific patient populations.

Who Should Pay Closer Attention

Patients on sirolimus for renal transplant who are also on hormone-sensitive therapy, patients using sirolimus off-label alongside TRT or HRT protocols, and individuals with hormone-receptor-positive malignancies should discuss resveratrol's estrogenic activity separately from its CYP3A4 effects. Resveratrol's estrogen-receptor binding does not directly alter sirolimus pharmacokinetics, but it adds a second layer of complexity that a prescribing clinician needs to know about.

Does Resveratrol Affect Sirolimus Differently Depending on the Formulation?

Standard sirolimus (Rapamune) already has highly variable oral bioavailability, the coefficient of variation for AUC is approximately 40% across individuals (2). This baseline variability means that the same resveratrol dose could raise trough levels modestly in one person and substantially in another, depending on baseline CYP3A4 activity, gut transit time, and individual P-gp expression.

Nanoparticle and Liposomal Resveratrol Formulations

High-bioavailability resveratrol products (e.g., NovaSol, Longevinex with cyclodextrin) increase resveratrol plasma concentrations significantly compared with standard powder capsules. One pharmacokinetic study found a 370-fold increase in plasma resveratrol concentration with a micellar formulation relative to unformulated resveratrol (10). Higher resveratrol plasma levels mean more enzyme inhibition, which translates to a proportionally greater effect on sirolimus trough concentrations. Patients using high-bioavailability resveratrol products face a larger pharmacokinetic risk than patients using standard capsules.

What Clinical Monitoring Is Needed?

Any patient combining resveratrol with sirolimus should have sirolimus whole-blood trough levels checked before adding resveratrol and again 10 to 14 days after starting it (or changing the resveratrol dose or formulation). This timing aligns with sirolimus's half-life of approximately 62 hours, which means steady-state is reached in roughly 5 to 6 days (2).

Trough Timing and Lab Interpretation

Sirolimus troughs are drawn just before the next dose (for daily dosing) or at the same time each week (for weekly longevity dosing). The laboratory should use a validated HPLC-MS/MS or immunoassay method. Whole-blood samples, not plasma, are required because sirolimus partitions heavily into red blood cells, a plasma sample underestimates true exposure by roughly 95%.

Signs of Sirolimus Toxicity to Watch For

Elevated trough levels increase the risk of oral ulcers (aphthous stomatitis), hyperlipidemia (sirolimus raises LDL and triglycerides in a dose-dependent fashion), thrombocytopenia, and impaired wound healing. If a patient starts resveratrol and develops any of these signs, a sirolimus trough should be drawn the same day.

Drug-Interaction Database Classifications

The Natural Medicines database classifies the resveratrol-sirolimus combination as a "moderate" interaction based on the CYP3A4 and P-gp inhibition evidence. The interaction is rated as likely clinically significant, though direct human pharmacokinetic data are absent. The American Society of Transplantation guidelines do not specifically address resveratrol, but the broader principle stated in the Rapamune prescribing label applies: "avoid or closely monitor drugs known to inhibit CYP3A4 or P-gp" (2).

The table below summarizes HealthRX's clinical decision framework for patients asking about this combination. This framework was developed by the HealthRX medical team based on a synthesis of the pharmacokinetic literature, the Rapamune prescribing label, and Natural Medicines database guidance, it does not represent published guideline content.

| Patient Scenario | Recommended Action | |---|---| | Transplant recipient on sirolimus, stable troughs | Do not add resveratrol without nephrology or transplant team sign-off. Obtain trough before and 2 weeks after any change. | | Off-label longevity user, weekly low-dose sirolimus | Discuss with prescribing physician. If approved, start standard-bioavailability resveratrol at 100 to 250 mg/day; check trough at 2 weeks. | | High-bioavailability resveratrol product (micellar, liposomal) | Treat as a higher-risk CYP3A4 inhibitor. Reduce sirolimus dose proactively or avoid the combination entirely. | | Patient stopping resveratrol after stable combined use | Check sirolimus trough 10 to 14 days after discontinuation. Levels may fall; dose adjustment may be needed in the opposite direction. |

What Happens When You Stop Resveratrol?

This point is missed in most supplement-drug interaction discussions. When resveratrol is discontinued, CYP3A4 activity recovers over days to weeks, depending on the formulation and individual enzyme turnover. Sirolimus trough levels will fall as clearance normalizes. In a transplant patient whose dose was kept constant while resveratrol was suppressing clearance, stopping resveratrol abruptly can cause trough levels to drop below the therapeutic range, a scenario that increases acute rejection risk.

Off-label longevity users face a lower absolute risk but should still be aware that removing resveratrol from their stack is not a neutral pharmacokinetic event. The clinical instruction is the same: check troughs 10 to 14 days after stopping resveratrol, just as you would after starting it.

What the Research Still Cannot Tell Us

The most honest thing to say about this combination is that no human pharmacokinetic trial has directly measured the interaction. The risk estimate of a 30 to 70% increase in sirolimus AUC is extrapolated from in vitro enzyme kinetics and from studies with other moderate CYP3A4 inhibitors, not from a controlled crossover study in humans. Resveratrol's bioavailability from standard capsules is also notoriously low (roughly 1% for unformulated trans-resveratrol), which means that at standard doses the plasma inhibitor concentration may be too low to produce meaningful CYP3A4 inhibition in most people.

The uncertainty cuts both ways. Resveratrol may matter less than the pharmacology predicts at typical supplement doses, or it may matter more in individuals with naturally low baseline CYP3A4 activity, which affects roughly 10 to 15% of the population due to CYP3A4 polymorphisms (11). There is no way to know without measuring trough levels.

Practical Guidance for Patients Already Taking Both

If you are already taking both sirolimus and resveratrol and have not had a sirolimus trough checked recently, get one measured at your next available appointment. Do not stop resveratrol abruptly (particularly in the transplant setting) without discussing it with your physician, because the resulting drop in sirolimus levels carries its own risk.

Steps to Take Before Your Appointment

Bring the exact resveratrol product (brand, dose, formulation), the sirolimus dose and schedule, and any other supplements or grapefruit products you take regularly. Grapefruit and Seville oranges also inhibit CYP3A4 and P-gp, and their combined effect with resveratrol on sirolimus levels is completely uncharacterized. Disclosing all three together gives your prescribing physician the complete picture.

After Stabilization

Once trough levels are confirmed stable and within the target range on the combined regimen, the monitoring interval can return to the normal schedule. Any change in resveratrol dose, brand, or formulation should trigger a repeat trough check at 10 to 14 days, treated identically to a sirolimus dose change.